secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-10-19T23:59:59+00:00
Accession:  0001193125-23-258963
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam cuts ~20% workforce (100 roles), focuses on sickle cell, AATD, extends cash runway into 2026
--------------------------------------------------------------------------------

- Reduces headcount by ~100 employees (20%), expects $6.6M in Q4 2023 severance costs.
- Prioritizes BEAM-101, ESCAPE, and in vivo sickle cell programs; BEAM-302 for AATD.
- Explores partnerships for BEAM-201 and other CAR-T programs; pauses hepatitis B program.
- Cash, equivalents, and securities of $1.1B (June 30, 2023) expected to fund operations into 2026.
- Strategic restructuring aims to streamline operations and focus on near-term value drivers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/0001193125-23-258963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/d517250d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-258963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer